Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

August 12, 2020

Primary Completion Date

June 19, 2024

Study Completion Date

June 19, 2024

Conditions
Venous Thromboembolism
Interventions
DRUG

Apixaban 2.5 MG Oral Tablet

Patients will be assigned to the respective study groups postoperatively upon arrival in the post-anesthesia care unit. Hence, surgeons are blinded at the time of surgery as to study group assignment. Chemoprophylaxis will continue for the duration of the hospitalization.

DRUG

Enoxaparin 40Mg/0.4mL Prefilled Syringe

Patients will be assigned to the respective study groups postoperatively upon arrival in the post-anesthesia care unit. Hence, surgeons are blinded at the time of surgery as to study group assignment. Chemoprophylaxis will continue for the duration of the hospitalization.

Trial Locations (1)

94305

Stanford University Medical Center, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT04504318 - Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT | Biotech Hunter | Biotech Hunter